Skip to main content
. 2024 May 7;15(3):432–453. doi: 10.14740/wjon1845

Table 5. Demographics and Clinical Characteristics for Pancreatic Cancer by Histology.

Pancreas All Adenocarcinoma Squamous Adenosquamous P value
N (%) 250,034 (100.0) 149,409 (59.8) 530 (0.2) 1,273 (0.5)
Age (years) (%)
  0 - 14 94 (< 1) 1 (< 1) 0 (0.0) 0 (0.0) 0.66
  15 - 29 696 (0.3) 94 (0.1) 0 (0.0) 0 (0.0)
  30 - 49 14,416 (5.8) 7,915 (5.3) 33 (6.2) 70 (5.5)
  50 - 69 105,829 (42.3) 68,078 (45.6) 220 (41.5) 564 (44.3)
  70 - 89 128,999 (51.6) 73,321 (49.1) 277 (52.3) 639 (50.2)
  Mean (SD) 68.9 (11.8) 68.4 (11.1) 68.6 (11.5) 68.4 (10.5) 0.91
  Median 70 69 70 70
Sex (%)
  Male 128,060 (51.2) 77,717 (52.0) 282 (53.2) 671 (52.7) 0.76
  Female 121,974 (48.8) 71,692 (48.0) 248 (46.8) 602 (47.3)
Race (%)
  White 203,422 (81.4) 121,475 (81.3) 403 (76.0) 1,027 (80.7) 0.032
  Black 26,897 (10.8) 16,531 (11.1) 74 (14.0) 140 (11.0)
  Other 19,715 (7.9) 11,403 (7.6) 53 (10.0) 106 (8.3)
Detection stage (%)
  Localized 26,418 (10.6) 11,737 (7.9) 30 (5.7) 112 (8.8) < 0.001
  Regional 68,912 (27.6) 43,426 (29.1) 133 (25.1) 488 (38.3)
  Distant 129,160 (51.7) 86,543 (57.9) 329 (62.1) 632 (49.6)
  Unstaged 25,544 (10.2) 7,703 (5.2) 38 (7.2) 41 (3.2)
Grade differentiation (%)
  Well 14,289 (5.7) 5,895 (3.9) 14 (2.6) 6 (0.5) < 0.001
  Moderate 31,406 (12.6) 19,930 (13.3) 42 (7.9) 148 (11.6)
  Poor 34,609 (13.8) 22,413 (15.0) 163 (30.8) 429 (33.7)
  Unknown 169,730 (67.9) 101,171 (67.7) 311 (58.7) 690 (54.2)
Surgery (%)
  Yes 44,939 (18.0) 19,802 (13.3) 45 (8.5) 461 (36.2) < 0.001
  No 205,095 (82.0) 129,607 (86.7) 485 (91.5) 812 (63.8)
Chemotherapy (%)
  Yes 105,126 (42.0) 75,021 (50.2) 219 (41.3) 703 (55.2) < 0.001
  No 144,908 (58.0) 74,388 (49.2) 311 (58.7) 570 (44.8)
Radiotherapy (%)
  Yes 34,417 (13.8) 24,021 (16.1) 86 (16.2) 207 (16.3) 0.98
  No 215,617 (86.2) 125,388 (83.9) 444 (83.8) 1,066 (83.7)
Incidence rate (95% CI) -
  All 123.6 (123.1 - 124.1) 71.2 (70.9 - 71.7) 0.23 (0.21 - 0.25) 0.63 (0.59 - 0.66)
  Male 140.3 (139.4 - 141.1) 82.1 (81.5 - 82.8) 0.28 (0.24 - 0.32) 0.73 (0.67 - 0.79)
  Female 109.7 (109.1 - 110.4) 62.3 (61.8 - 62.8) 0.19 (0.16 - 0.22) 0.54 (0.50 - 0.59)
CSS (95% CI) -
  1-year 32.0 (31.8 - 32.2) 28.0 (27.7 - 28.3) 17.7 (13.5 - 22.4) 27.7 (24.7 - 30.8)
  2-year 17.6 (17.4 - 17.8) 11.5 (11.3 - 11.7) 7.2 (4.5 - 10.7) 13.4 (11.1 - 16.0)
  5-year 9.6 (9.4 - 9.7) 3.9 (3.8 - 4.0) 3.3 (1.6 - 6.2) 6.7 (4.9 - 8.8)
  10-year 7.3 (7.1 - 7.4) 2.6 (2.5 - 2.7) 3.3 (1.6 - 6.2) 4.7 (3.0 - 7.0)
  Median (months) 5.9 5.7 3.7 5.9
RS (95% CI) -
  1-year 30.3 (30.0 - 30.5) 26.6 (26.3 - 26.9) 16.4 (12.5 - 20.9) 26.5 (23.6 - 29.5)
  2-year 16.1 (16.0 - 16.3) 10.5 (10.4 - 10.7) 6.4 (4.0 - 9.7) 12.4 (10.2 - 14.8)
  5-year 8.1 (7.9 - 8.2) 3.3 (3.1 - 3.4) 2.7 (1.2 - 5.2) 5.7 (4.1 - 7.6)
  10-year 5.1 (5.0 - 5.3) 1.7 (1.6 - 1.9) 2.7 (1.2 - 5.2) 3.2 (1.9 - 5.1)
  Median (months) 5.4 5.4 3.6 5.7

P < 0.05 for all comparisons between adenocarcinoma, squamous cell carcinoma and adenosquamous cell carcinoma comparisons. Incidence rates were expressed per 100,000. CSS: cause-specific survival; RS: relative survival; CI: confidence interval; SD: standard deviation.